NeOnc Technologies secured two Investigational New Drug (IND) authorizations in the UAE for its brain cancer therapies NEO100 and NEO212, expanding its international clinical development. The NEO100 IND covers adult and pediatric studies, including Phase 1 and Phase 2 trials, with topline Phase 2a results expected by July for recurrent high-grade gliomas. These approvals complement existing FDA designations, potentially accelerating regulatory pathways and commercialization. Insider buying and institutional support highlight growing investor confidence as NeOnc prepares for multiple clinical and regulatory catalysts through 2026.
The global off-highway fluid management market is projected to grow from $1.21 billion in 2026 to $1.63 billion by 2032, at a CAGR of 4.8%. Growth is fueled by increased focus on equipment reliability, demand for durable fluid systems in rental model...
A class action lawsuit has been filed against First Solar, alleging the company made false and misleading statements about its ability to manage the impact of U.S. tariff policies. The lawsuit claims First Solar overstated its capacity to handle tari...
The global market for kids sports equipment and accessories is projected to grow from $4.2 billion in 2025 to $5.5 billion by 2032, at a CAGR of 3.9%. Growth is fueled by increased investment in school and community sports programs, rising parental f...
The global digital health market for musculoskeletal care is projected to grow from $3.8 billion in 2025 to $10.9 billion by 2032, at a CAGR of 16.4%. Growth is fueled by rising musculoskeletal disorders, adoption of AI-driven remote physiotherapy, w...
The global LoRaWAN market is projected to grow from an estimated $3.6 billion in 2025 to $44.2 billion by 2032, with a compound annual growth rate of 43.1%. This rapid expansion is fueled by increasing adoption of IoT technologies, smart city project...
